Serum Institute of India applies for license for JN.1 Covid variant vaccine: Report
COVID LIVE UPDATES A report by Moneycontrol mentioned that the Serum Institute of India (SII) currently offers a vaccine against the XBB1 variant of Covid-19, which is "similar" to the JN.1 variant. The spokesperson told the business website that SII would share the documents with the public once they are submitted to the regulators. Mint could not officially verify the report.
JN.1 Covid variant: Delhi, Kerala, and other states review coronavirus situation Serum Institute of India produced Covishield vaccines in partnership with AstraZeneca and Oxford University in 2020 during the pandemic. JN.1 Covid variant: 21 cases found in India, highest detected in THIS state Covishield was among the two made-in-India vaccines against coronavirus. Bharat Biotech's Covaxin was the second vaccine that was approved by India's drug regulatory body during the Covid pandemic in 2021 January.
The companies remarkably scaled up production and helped other nations too by exporting millions of vaccines. India dispatched Serum-made Covishield vaccines to Bangladesh, Myanmar, Nepal, Maldives, Mauritius, Afghanistan, Egypt, Ukraine, New Zealand, and 92 other countries. India has so far confirmed 21 cases of the JN.1 Covid variant.
The World Health Organization (WHO) recently classified JN.1 as a variant of interest. However, the global health body emphasised that the overall risk posed by JN.1 remains low based on current evidence. Covid cases in India: 328 active cases detected in 24 hours; Rajasthan reports 4 cases of JN.1 India registered 2,669 new Covid cases on Friday.
Read more on livemint.com
